logo
Wimbledon's robot line judges caught napping on Centre Court

Wimbledon's robot line judges caught napping on Centre Court

Digital Trends2 days ago
Following in the footsteps of the U.S. Open and the Australian Open, Wimbledon finally did away with human line judges in favor of Hawk-Eye technology at this year's Championships.
All 18 courts have incorporated the system, which uses multiple high‑speed cameras and real‑time computer vision algorithms, with loudspeakers emitting an audible 'out' to confirm a missed shot.
Recommended Videos
A week into this year's competition, the technology appeared to be working well. But then, during a high-profile match on Centre Court on Sunday involving Brit Sonay Kartal and Russian Anastasia Pavlyuchenkova, the system seemed to go a bit quiet, with the umpire having to confirm a couple of widely missed shots as out.
But then, a short while later, on a game point for Pavlyuchenkova toward the end of the first set, Hawk-Eye failed to call a ball hit by Kartal that landed a foot past the baseline, with Pavlyuchenkova half-heartedly keeping it in play. Despite having clearly won the point — and therefore the game — Pavlyuchenkova was told to replay it. She lost the point and went on to lose the game.
It was a confusing mess, with Pavlyuchenkova complaining during the changeover that 'they stole the game from me.'
Fortunately for the Russian, she managed to retain a cool head and went on to win the match. But it could have turned out very differently.
The All England Club, which runs Wimbledon, said at first that the system was 'deactivated on the point in question' because of 'operator error,' according to a BBC report.
A spokesperson said later on Sunday that, after further investigation, it was found the technology was 'deactivated in error on part of the server's side of the court for one game.'
The spokesperson added: 'We have apologized to the players involved. We continue to have full confidence in the accuracy of the ball-tracking technology. In this instance, there was a human error and as a consequence we have fully reviewed our processes and made the appropriate changes.'
Having overruled some earlier calls, it's not clear why the umpire failed to do the same for this shot, which was clearly out. The rulebook states that the umpire has the power to make a call if Hawk-Eye fails to do so.
'He also saw it out, he told me after the match,' Pavlyuchenkova said in a post-match press conference. 'I thought he would do that, but he didn't. Instead they just said replay. I don't know if it's something to do [with Kartal being] local. I think it's also difficult for him. He probably was scared to take such a big decision.'
Sunday's Hawk-Eye hiccup demonstrates that even automated line-calling systems are not infallible, a reality that, going forward, will put even greater pressure on the only human left officiating the match — the umpire. It'll be interesting to see how Pavlyuchenkova's experience affects next week's Wimbledon matches, with players perhaps more likely to look the umpire's way if they're expecting a shout from Hawk-Eye that doesn't come.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Glens beat Reds to go top of Women's Premiership
Glens beat Reds to go top of Women's Premiership

Yahoo

time38 minutes ago

  • Yahoo

Glens beat Reds to go top of Women's Premiership

Glentoran put recent cup heartache behind them with a 2-0 win over Cliftonville at Solitude on Tuesday to go top of the Women's Premiership. The east Belfast side were beaten 3-1 by Bohemians in the quarter-finals of the All-Island Cup on Saturday having thrown away a 2-0 half-time advantage against Cliftonville in the Women's League Cup final the week before. Advertisement But they exacted a measure of revenge for the latter of those two defeats when goals in each half from Jessica Foy and Demi Vance ensured a sixth win from six games in league action this season. In a meeting of the two sides who have shared the past five league titles, Foy opened the scoring just past the half-hour mark as she controlled a free-kick floated into the box and calmly slotted home. Vance doubled the visitors' advantage after the break when coming forward off the left flank and finishing well after a move across the box. Kim Turner's side are two points clear of second-place Linfield with Cliftonville a further three back, although the Blues have played a game more.

Wimbledon 2025 bracket: Quarterfinal results, schedule through finals
Wimbledon 2025 bracket: Quarterfinal results, schedule through finals

USA Today

time41 minutes ago

  • USA Today

Wimbledon 2025 bracket: Quarterfinal results, schedule through finals

The 2025 Wimbledon championships have already produced plenty of drama and upsets in the men's and women's singles tournaments, and the final rounds are shaping up for more of the same. The quarterfinal round is halfway done at the only tennis major played on grass courts each year, and already there are some highly anticipated matches set up for the semifinals. Americans Taylor Fritz and Amanda Anisimova both secured a spot in the final four with quarterfinal wins on Tuesday, with Fritz set to face No. 2 seed and defending Wimbledon champion Carlos Alcaraz in the men's draw and No. 1 seed Aryna Sabalenka awaiting Anisimova in the women's draw, with a spot in the Wimbledon final on the line. There are also two more quarterfinal matches to be played on Wednesday, with men's No. 1 seed Jannik Sinner, battling an elbow injury, taking on American Ben Shelton. Novak Djokovic is seeking his eighth Wimbledon title and remains alive with a quarterfinal match against Italian Flavio Cobolli on tap. Here's a look at the updated bracket and schedule for the men's and women's singles competition at the 2025 Wimbledon championships, including scores and results through matches on Tuesday, July 8. BEN SHELTON: Credits football background as QB for serving prowess at Wimbledon LAST AMERICAN TO WIN WIMBLEDON: Taylor Fritz, Ben Shelton looking to end drought Wimbledon 2025 schedule: Bracket update for men's and women's singles All times EDT Watch 2025 Wimbledon with Fubo Wimbledon 2025 scores: Latest results for men's and women's singles Quarterfinals Fourth Round CLICK HERE: For complete Wimbledon men's singles results Quarterfinals Fourth Round CLICK HERE: For complete Wimbledon women's singles results

Plexāā Closes $4.5 Million Funding Extension to Drive U.S. Launch of BLOOM43 Platform for Breast Surgery
Plexāā Closes $4.5 Million Funding Extension to Drive U.S. Launch of BLOOM43 Platform for Breast Surgery

Yahoo

time41 minutes ago

  • Yahoo

Plexāā Closes $4.5 Million Funding Extension to Drive U.S. Launch of BLOOM43 Platform for Breast Surgery

LONDON, July 08, 2025--(BUSINESS WIRE)--Plexāā, a MedTech startup behind the award-winning BLOOM43 medical device for breast surgery, has announced the close of a $4.5 million funding extension round. The strategic capital infusion will support the imminent U.S. launch of BLOOM43, while also laying the groundwork for future innovations. The funding also strengthens the company's position ahead of their planned Series A fundraising round. Complication rates in breast surgeries, which can include infection, skin necrosis and the need for additional surgeries, have been recorded as high as 30 percent.1 BLOOM43 is the world's first fully wearable medical device designed to help patients prepare for breast cancer surgery and reconstruction by harnessing the power of Supraphysiological Preconditioning™. The new technique safely and intermittently thermally preconditions the skin causing the release of heat-shock proteins that cause vasodilation and increased blood flow to the area. This process has been shown to reduce wound healing complications in proof-of-concept clinical trials. Along with its BLOOM43 companion app, the device has demonstrated substantial improvements in the patient experience and surgical readiness, harnessing the power of holistic Prehabilitation™ and preconditioning. The company has already secured multiple partners for its upcoming U.S. commercial launch. "I want to thank our team for the tremendous progress it has made to make this financing possible," said Dr. Saahil Mehta, founder and CEO of Plexāā. "Securing this funding validates confidence in our flagship technology and the concept of Supraphysiological Preconditioning™, and it energizes the team as we prepare to bring BLOOM43 to a wider patient population in the U.S. and beyond. The funds will support this pivotal launch and market expansion, as well as the exciting development of our technology platform – including devices and apps targeting additional surgical specialties and creating a whole new category in surgery." Plexāā Ltd has been backed by TCP Health Ventures (the dedicated healthcare investment arm of The Capital Partnership group of companies) who led the Seed Round. This extension round comprises existing and new investors including TCP. Further investment includes over $1.6 million in i4i grant funding from the National Institute for Health and Care Research (NIHR), and $1.3 million from Thena Capital, a London-based VC firm backed by the British Business Bank and focused on digital health and fast-tracked Medtech. Tatum Getty, founding General Partner at THENA Capital added, "Since 2023, we've been closely tracking Plexāā's progress and the development of its first device, BLOOM43. We couldn't be more excited for Plexāā to become our first portfolio company for THENA Capital's Fund I. The company is solving a critical and under-addressed challenge across the surgical pathway- reducing post-operative complications for patients which also addresses the impact to both providers and payers. "Saahil and his team bring together clinical, engineering, and operational expertise from some of the UK's leading institutions. Their bold ambition to scale globally, beginning with an imminent commercial launch in the U.S., is exactly the kind of UK MedTech leadership team we look to champion. Our fund's commercialisation support model is well-suited to help Plexāā expand into women's health and adjacent categories where better outcomes and patient experiences are urgently needed." Plexāā plans to collaborate with clinicians, patients, and partners worldwide to make prehabilitation and preconditioning the standard of care for surgery — and to deliver transformative solutions that address unmet needs in surgical care. About Plexāā Plexāā is a pioneering UK-based MedTech company focused on improving surgical outcomes through devices and digital products. Its flagship device, BLOOM43, enables patients to supraphysiologically precondition their skin, potentially reducing the risk of wound healing complications such as infection and skin necrosis, which affect one in three women undergoing breast surgery. Plexāā is also exploring the application of this technology in other surgical fields, including obstetrics for C-sections, orthopaedics for joint operations, and general and vascular surgery, with a commitment to improving pre-operative preparation for surgery and patient outcomes. About TCP Health Ventures TCP Health Ventures is the dedicated healthcare investment arm of The Capital Partnership group of companies, a multi-asset investment company with assets under management of $7 billion. Headquartered out of London, TCP Health Ventures manages assets of $ 225 million across 15+ investments in the med-tech space and has a med-tech investing experience of 10 years. About the NIHR The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by: Funding high quality, timely research that benefits the NHS, public health and social care; Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services; Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research; Attracting, training and supporting the best researchers to tackle complex health and social care challenges; Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system; Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries. NIHR is funded by the Department of Health and Social Care. Its work in low- and middle- income countries is principally funded through UK international development funding from the UK government. About THENA Capital THENA Capital is a London-based venture capital firm backing the world's next category-defining medical technologies. We invest in breakthrough companies transforming care experiences through digital health, fast-tracked medical devices, and clinical-grade innovation. THENA's debut Fund 1, focuses on high-impact, UK-founded technologies addressing unmet needs across women's health, oncology, cardiovascular disease, chronic conditions, and care delivery. With deep clinical, regulatory and operational expertise, THENA Capital partners with founders to unlock international scale, navigate complex markets, and build enduring category leaders in global healthcare. References 1 Annals of Translational Medicine, Dec 2023, Management of complications following implant-based breast reconstruction: a narrative review, Dean H. Meshkin1^, Joseph M. Firriolo1, Nolan S. Karp2, Ara A. Salibian1 View source version on Contacts Media Contacts: Sam ChoinskiPazanga Health CommunicationsSchoinski@ (860) 301-5058marketing@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store